In this case report, a previously healthy male child with infarctions due to pulmonary embolism, a history of MIS-C, and thrombi in the tricuspid valve and the superior sagittal sinus is presented.
Figure 3: Formation of a 10x8 mm thrombus on the tricuspid cover, area origin from the right atrium.
Case series on the MIS-C with COVID-19 have reported high D-dimer and fibrinogen levels;[5] however, little is known about the exact pathophysiology or the long-term implications of MIS-C, and it is unclear at this time what role SARS-CoV-2 may play in thrombophilia. In an analysis of a national multicenter registry of children and adolescents with MIS-C in the United States, the rate of symptomatic VTE was 7% (3/45) among patients 13 to 21 years of age and 1.3% (1/75) in children 5 to 13 years old.[4] A right atrial thrombus was detected in a 12-year-old previously healthy patient treated with extracorporeal membrane oxygenation (ECMO) after MIS-C in a pediatric intensive care unit, and in another 14-year-old intensive care patient, cranial CT demonstrated acute right anterior and middle cerebral artery territory infarctions.[5] In these two cases, it was determined that thrombosis developed despite heparin doses that were higher than the average for the ECMO population, and fibrinogen levels were markedly higher than in patients without MIS-C undergoing ECMO.[5] Another case is of an 11-year-old male in whom echocardiography revealed a large thrombus in the right atrium, who was then successfully treated with cardiac surgery.[6]
The floppy and pedunculated mass that prolapsed into the right atrium during systole demonstrated by transesophageal echocardiography and the possibility of the migration of this mass were accepted as indications for surgery in our case. In the literature, no other similar case with multiple thrombi and without symptoms has been reported.
In conclusion, there is an increasing concern about hypercoagulation and acute thrombosis in pediatric patients with COVID-19 infection; however, no clinical studies on the efficacy and safety of anticoagulant thromboprophylaxis or antithrombotic therapy in children with COVID-19 or MIS-C have been published. In addition, the long-term effects of MIS-C are not yet thoroughly known; therefore, laboratory parameters and cardiological control follow-ups of these cases must be extended, regardless of the presence of symptoms.
Acknowledgements: We thank Mehmet Çoşkun for his valuable contribution to the radiological interpretation and Malik Ergin for his valuable contribution to the pathology images and interpretations.
Patient Consent for Publication: A written informed consent was obtained from each patient.
Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Author Contributions: Contributed to the design and implementation, to the analysis of the results and to the writing of the manuscript - A.A.K., E.K., C.Z., Y.O., M.K.
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Funding: The authors received no financial support for the research and/or authorship of this article.
1) Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar
AP, Müller MCA, et al. Incidence of venous thromboembolism
in hospitalized patients with COVID-19. J Thromb Haemost
2020;18:1995-2002.
2) CDC Health Alert Network. Mulitsystem Inflammatory
Syndrome in Children (MIS-C) Associated with Coronavirus
Disease 2019 (COVID-19). Available at: https://emergency.cdc.
gov/han/2020/han00432.asp [Accessed: February 13, 2021]
3) Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS,
Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic
complications in critically ill ICU patients with COVID-19.
Thromb Res 2020;191:145-7.
4) Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams
MM, Son MBF, et al. Multisystem inflammatory syndrome in
U.S. children and adolescents. N Engl J Med 2020;383:334-46.